CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $210.59M, lower than 95% of all stocks globally
- PositionOperating margin is -7051%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
210.59MUSDvs all stocks (USD)
Revenue (TTM)
33.18MUSDvs all stocks (USD)
Profit Margin
-256.60%vs Biotechnology peers
Beta
0.9700xvs all stocks
52-Week Change
-22.84%vs all stocks
Market Capitalization
210.59MUSDvs all stocks (USD)
Enterprise Value
-55.19MUSDvs all stocks (USD)
Forward P/E
-1.90xvs Biotechnology peers
Price to Sales (TTM)
6.33xvs Biotechnology peers
Price to Book (MRQ)
0.7330xvs Biotechnology peers
Enterprise to Revenue
-1.66xvs Biotechnology peers
Enterprise to EBITDA
0.5220xvs Biotechnology peers
Profit Margin
-256.60%vs Biotechnology peers
Return on Assets (TTM)
-12.23%vs Biotechnology peers
Return on Equity (TTM)
-16.79%vs Biotechnology peers
Revenue (TTM)
33.18MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.04USDUpdated Jul 19, 2026Quarterly Revenue Growth
-99.80%vs Biotechnology peers
Gross Profit (TTM)
-61.35MUSDvs all stocks (USD)
EBITDA (TTM)
44.21MUSDvs all stocks (USD)
Net Income (TTM)
-85.14MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-99.83%vs Biotechnology peers
Operating Cash Flow (TTM)
-57.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-37.69MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
244.06MUSDFY2025 · Dec 31, 2025Operating Income
67.57MUSDvs all stocks (USD)
Pre-tax Income
91.90MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.88MUSDFY2025 · Dec 31, 2025Net Income
87.01MUSDFY2025 · Dec 31, 2025EBIT
67.57MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
44.21MUSDFY2025 · Dec 31, 2025Research & Development
129.64MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
46.85MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
87.01MUSDFY2025 · Dec 31, 2025Operating Cash Flow
113.63MUSDFY2025 · Dec 31, 2025Free Cash Flow
112.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
288.86MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.14MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
87.01MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.70MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.08MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
78.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.55MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.55MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-375.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-378.76MUSDFY2025 · Dec 31, 2025Shares Outstanding
19.73MSharesUpdated Jul 19, 2026Float Shares
17.80MSharesUpdated Jul 19, 2026Shares Short
1.03MSharesUpdated Jul 19, 2026Short Ratio
3.35daysvs all stocks
Short % of Shares Outstanding
5.97%vs all stocks
% Held by Insiders
3.71%vs all stocks
% Held by Institutions
95.12%vs all stocks
Total Cash (MRQ)
281.50MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
14.22USDUpdated Jul 19, 2026Total Debt (MRQ)
16.31MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0571xvs Biotechnology peers
Current Ratio (MRQ)
22.61xvs Biotechnology peers
Book Value per Share (MRQ)
14.47USDUpdated Jul 19, 2026Total Assets
338.02MUSDvs all stocks (USD)
Total Current Assets
315.43MUSDFY2025 · Dec 31, 2025Total Liabilities
34.89MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.59MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
287.42MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.57MUSDFY2025 · Dec 31, 2025Accounts Payable
1.97MUSDFY2025 · Dec 31, 2025Short-term Debt
2.41MUSDFY2025 · Dec 31, 2025Other Current Liabilities
217.00KUSDFY2025 · Dec 31, 2025Long-term Debt
14.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-481.76MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
303.13MUSDvs all stocks (USD)
Treasury Stock
384.56MUSDFY2025 · Dec 31, 202552-Week Low
9.69USDUpdated Jul 19, 202652-Week High
22.55USDUpdated Jul 19, 202652-Week Change
-22.84%vs all stocks
Beta
0.9700xvs all stocks
50-Day MA
10.94USDUpdated Jul 19, 2026200-Day MA
14.55USDUpdated Jul 19, 2026Avg 10-Day Volume
266.46KSharesUpdated Jul 19, 2026Avg 30-Day Volume
292.37KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.53USDUpdated Jul 19, 2026Other Income / Expense
24.33MUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cumulative Treasury Stock Significant With Elevated ROE And FCF-To-Equity
It has bought back shares for years, and its equity earns more than its industry and yields heavy free cash flow.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -7051%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -70.51Industry median: -0.34Industry P5: -43.55Peers compared: 261
Price-to-book is 0.73×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.73Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 1.78Revenue Growth YoY: -1.00
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Altman Z-Score 4.05: safe zoneNotable
Altman Z-Score: 4.05
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $210.59M, lower than 95% of all stocks globallySignificant
Market cap (USD): 210,585,145Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avidity Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Deckers Outdoor Corporation
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsIndustry-Benchmarked Return on Capital Elevated
Sk Biopharmaceuticals Co., Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital Elevated
Garmin Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital Elevated